(Q39484177)

English

The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21869836%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21869836%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

lymphoblastic leukemia

1 reference

based on heuristic

inferred from title

Jacques Van Dongen

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21869836%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

author name string

J F de Vries

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21869836%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

C M Zwaan

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21869836%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

M De Bie

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21869836%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

J S A Voerman

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21869836%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

M L den Boer

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21869836%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

V H J van der Velden

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21869836%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

publication date

26 August 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21869836%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21869836%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

26

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21869836%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21869836%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

255-264

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21869836%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

https://scigraph.springernature.com/pub.10.1038/leu.2011.206

0 references

Childhood cancer survival: a report from the United Kingdom Childhood Cancer Study.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.206

21 January 2018

Treatment of acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.206

21 January 2018

Biology and treatment of acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.206

21 January 2018

Treating childhood acute lymphoblastic leukemia without cranial irradiation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.206

21 January 2018

Pathogenesis of cardiotoxicity induced by anthracyclines

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.206

21 January 2018

Maximizing the delivery of intraperitoneal therapy while minimizing drug toxicity and maintaining quality of life

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.206

21 January 2018

Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.206

21 January 2018

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.206

21 January 2018

Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.206

21 January 2018

Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.206

21 January 2018

CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.206

21 January 2018

CD22 as a target of passive immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.206

21 January 2018

Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.206

21 January 2018

Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.206

21 January 2018

High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.206

21 January 2018

Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.206

21 January 2018

Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.206

21 January 2018

DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.206

21 January 2018

A new type of radiosensitive T-B-NK+ severe combined immunodeficiency caused by a LIG4 mutation.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.206

21 January 2018

Photoconversion of Lysotracker Red to a green fluorescent molecule.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.206

21 January 2018

Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.206

21 January 2018

CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.206

21 January 2018

CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.206

21 January 2018

Prognostic significance of multidrug resistance-related proteins in childhood acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.206

21 January 2018

Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.206

21 January 2018

Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.206

21 January 2018

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.206

21 January 2018

Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.206

21 January 2018

The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.206

21 January 2018

Exposure to anthracyclines during childhood causes cardiac injury

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.206

7 January 2021

based on heuristic

inferred from DOI database lookup

Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.206

7 January 2021

based on heuristic

inferred from DOI database lookup

Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.206

7 January 2021

based on heuristic

inferred from DOI database lookup

Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.206

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.206

7 January 2021

based on heuristic

inferred from DOI database lookup

Identification of candidate target antigens for antibody-based immunotherapy in childhood B-cell precursor ALL

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.206

7 January 2021

based on heuristic

inferred from DOI database lookup

Differential activation of the death receptor pathway in human target cells induced by cytotoxic T lymphocytes showing different kinetics of killing

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.206

7 January 2021

based on heuristic

inferred from DOI database lookup

Large interindividual differences in cellular sensitivity to calicheamicin may influence gemtuzumab ozogamicin response in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.206

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/LEU.2011.206

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21869836%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21869836%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39484177&oldid=1525855590"